Biogen (BIIB) Reiterated at Market Perform by BMO Capital, Zuranolone Looks Approvable in MDD, but Incremental Positive Doesn't Change Challenging Narrative Around Biogen
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $238.00 price target on Biogen (NASDAQ: BIIB), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
